myirislogo
03 July, 2015 16:10 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Hindalco In 110.55 0.54
State Bank O 268.85 0.54
Reliance 1006.75 0.35
Tata Stl 300.95 1.13
Icici Bank 314.35 0.45
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Shasun Pharmaceuticals Limited
Shasun Pharmaceuticals Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:524552NSE:SHASUNPHARBloomberg:SAPH@INReuters:SHAS.BO
Market Lot: 1Face Value: 2ISIN Demat: INE317A01028
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
29-SEP-14 Strides Arcolab and Shasun Pharmaceuticals today announced that the board of directors of both the companies have approved a scheme of amalgamation between the two companies. The combination creates a vertically integrated pharma company of scale with strong presence in Front-ended Regulated Markets Finished Dosages, Emerging Markets Branded Generics, Institutional Business, Active Pharmaceutical Ingredients and Contract Research and ...   More..
Business Profile Future Plans
CEO Talk
Shasun Chemicals and Drugs Ltd, while focusing on the bulk drugs business, expects increased contribution from the contract research business. The bulk drugs business, including the biotech sector, will continue to be its major focus in the years to come.   S. Vimal Kumar
One To One
Recent news
Latest News
Strides, Shasun Pharma gain post amalgamation  -IRIS 29-Sep-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2015(12)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 10243.108816.207290.20
Other Income146.50122.70136.60
Total Income10389.608938.907426.80
Cost of goods sold9662.308452.707146.30
OPBDIT727.30486.20280.50
PAT413.40352.30262.80
Gross Block---
Equity capital120.30113.30113.30
EPS (Rs.)-6.224.76
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-7.33 - 15.1412.69 - 39.05
Debt / Equity (x)---
Operating margin (% of OI) 7.0 5.4 3.8
Net margin (% of OI) 4.0 3.9 3.5
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Batra Centre
28 Sardar Patel Road
3rd and 4th floor
Guindy
Chennai
Tamil Nadu-600 032
PHONE
(044) 4344 6700
FAX
(044) 2235 0924/ 2235 0278
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer